Michael Ulz
Morgan Stanley, Research Division
All right. Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I’m Michael Ulz, one of the biotech analysts here. It’s my pleasure to introduce Gaurav Shah, CEO of Rocket Pharmaceuticals. Just a quick reminder, the format for today is a fireside chat. So if anyone has a question in the audience, please feel free to raise your hand, and we’ll address your questions during the discussion.
But before we get started, I just need to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. And with that, Gaurav, thanks again for joining us, and maybe I’ll hand it over to you to make some intro comments before we get into Q&A.
Gaurav Shah
CEO & Director
Thanks, Mike, for having us. Great to be here.
Big picture, Rocket Pharma is a gene therapy company. Our renewed and invigorated focus is on cardiovascular genetic medicines. We have 3 programs in the clinic, one hypertrophic, mostly cardiomyopathy called Danon disease, arrhythmogenic cardiomyopathy called PKP2 and dilated cardiomyopathy called BAG3, all are progressing rapidly. We also have a legacy pipeline of hematologic conditions. We just got an approval for severe LAD-1 called Kresladi earlier this year, for which we sold the PRV for $180 million.
We’re very proud of that. So at this point, we are an integrated company from discovery to commercialization from the beginning to end. Today was– is a very important
Read the full article here